Flexion Therapeutics, Inc. (NASDAQ:FLXN) received a $44.00 price target from equities research analysts at Royal Bank Of Canada in a report issued on Monday. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. Royal Bank Of Canada’s price target would indicate a potential upside of 89.17% from the stock’s current price.
FLXN has been the topic of a number of other research reports. Needham & Company LLC reaffirmed a “buy” rating and set a $34.00 price target on shares of Flexion Therapeutics in a report on Monday, May 15th. Cantor Fitzgerald set a $40.00 price objective on shares of Flexion Therapeutics and gave the stock a “buy” rating in a report on Monday, May 22nd. Zacks Investment Research downgraded shares of Flexion Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, July 13th. ValuEngine raised shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Finally, BMO Capital Markets reissued a “buy” rating on shares of Flexion Therapeutics in a report on Tuesday, June 27th. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $31.50.
Shares of Flexion Therapeutics (FLXN) opened at 23.26 on Monday. The company’s market cap is $742.11 million. Flexion Therapeutics has a 52-week low of $15.44 and a 52-week high of $29.41. The stock has a 50 day moving average of $23.31 and a 200 day moving average of $21.93.
Flexion Therapeutics (NASDAQ:FLXN) last announced its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.11). On average, equities research analysts expect that Flexion Therapeutics will post ($3.70) EPS for the current year.
COPYRIGHT VIOLATION WARNING: This piece of content was posted by Stock Observer and is the sole property of of Stock Observer. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://www.thestockobserver.com/2017/09/13/flexion-therapeutics-inc-flxn-pt-set-at-44-00-by-royal-bank-of-canada.html.
In other Flexion Therapeutics news, Director Mark Stejbach acquired 1,580 shares of the company’s stock in a transaction that occurred on Friday, June 16th. The shares were bought at an average price of $17.02 per share, with a total value of $26,891.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 15.98% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in FLXN. Teachers Advisors LLC raised its stake in Flexion Therapeutics by 21.2% during the 4th quarter. Teachers Advisors LLC now owns 43,468 shares of the specialty pharmaceutical company’s stock worth $827,000 after acquiring an additional 7,610 shares during the period. Janney Montgomery Scott LLC raised its stake in Flexion Therapeutics by 30.8% during the 1st quarter. Janney Montgomery Scott LLC now owns 13,575 shares of the specialty pharmaceutical company’s stock worth $365,000 after acquiring an additional 3,200 shares during the period. Wells Fargo & Company MN raised its stake in Flexion Therapeutics by 25.1% during the 1st quarter. Wells Fargo & Company MN now owns 124,717 shares of the specialty pharmaceutical company’s stock worth $3,356,000 after acquiring an additional 25,047 shares during the period. Canada Pension Plan Investment Board bought a new stake in Flexion Therapeutics during the 1st quarter worth approximately $2,018,000. Finally, Bank of New York Mellon Corp raised its stake in Flexion Therapeutics by 9.0% during the 1st quarter. Bank of New York Mellon Corp now owns 2,124,208 shares of the specialty pharmaceutical company’s stock worth $57,163,000 after acquiring an additional 175,879 shares during the period. Institutional investors own 82.75% of the company’s stock.
Flexion Therapeutics Company Profile
Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.
Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.